Predictive biomarkers for the efficacy of nivolumab as  ≥ third-line therapy in patients with advanced gastric cancer (AGC): From a subset analysis of ATTRACTION-2 phase III trial.

Authors

Jwa Hoon Kim

Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea, Republic of (South)

Jwa Hoon Kim , Min-Hee Ryu , Young Soo Park , Jungeun Ma , Sun Young Lee , Deokhoon Kim , Yoon-Koo Kang

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2023 ASCO Gastrointestinal Cancers Symposium

bookmark_border

Tumor mutational burden as a potential predictive marker for the efficacy of immunotherapy in advanced gastric cancer.

First Author: Jae Yeon Jang

insert_chart_outlined

Poster

2024 ASCO Gastrointestinal Cancers Symposium

bookmark_border

Nivolumab (NIVO) + chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 4 year (yr) follow-up of CheckMate 649.

First Author: Kohei Shitara

insert_chart_outlined

Poster

2024 ASCO Gastrointestinal Cancers Symposium

bookmark_border

First-line (1L) nivolumab (NIVO) plus chemotherapy (chemo) vs chemo in patients (pts) with advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma (GC/GEJC/EAC): CheckMate 649 Chinese subgroup analysis 4-year (yr) follow-up.

First Author: Lin Shen

insert_chart_outlined

Poster

2024 ASCO Gastrointestinal Cancers Symposium

bookmark_border

Efficacy and safety of nivolumab and CapeOX in patients with previously untreated FGFR2-positive, PD-L1-positive advanced gastric cancer: A single-arm, multicenter, phase 2 study NIVOFGFR2.

First Author: Ilya Tsimafeyeu